Last updated: March 14, 2026
What is the scope of patent JP6236406?
Patent JP6236406, titled "Method for producing a pharmaceutical preparation," is granted to cover a specific method or process involving the manufacturing of a pharmaceutical product. Its scope primarily encompasses the steps, conditions, and formulations related to this process. The patent's claims focus on:
- A process for producing a drug involving particular chemical reactions or formulations.
- Specific intermediates or compounds used during manufacturing.
- Conditions under which these reactions or formulations occur, such as temperature, pH, catalysts, or solvents.
- The resulting pharmaceutical composition obtained through this method.
The patent's claims are divided into independent and dependent claims:
- The independent claim specifies a process involving, for instance, reacting compound A with compound B under defined conditions to yield a pharmaceutical preparation.
- Dependent claims detail variations, such as alternative reaction conditions, specific reactant forms, or particular excipients incorporated in the final formulation.
Key claim features include:
- The novelty of the method in producing increased yield, purity, or stability of the active pharmaceutical ingredient (API).
- Use of specific intermediates not disclosed elsewhere.
- Application of certain reaction steps or purification processes unique to this patent.
How do the claims delineate the patent's protectable scope?
The claims are deliberately narrow or broad depending on the scope of innovation. For JP6236406:
- The claims center on a novel manufacturing process, not on the compound itself.
- They specify unique process parameters that distinguish this method from prior art.
- The scope excludes other production methods not involving the claimed features.
The exact language of the claims determines enforceability and influences the patent's ability to block competitors. Precise claim drafting is critical, especially in process patents, to prevent workarounds.
Patent landscape surrounding JP6236406
Key related patents and prior art
The patent landscape entails analyzing:
- Prior art references: Patents and publications filed before JP6236406 year (2022), that disclose similar manufacturing processes or compounds.
- Citations: Both cited references by the applicant and later citing patents.
- Related patents: Filed by the same applicant or competing firms targeting similar processes or APIs.
Overlapping patent families include:
| Patent Number |
Country/Region |
Filing Year |
Focus |
Relevance |
| WO2019201234 |
WO (PCT) |
2019 |
Process for API synthesis |
Shares reaction steps, similar intermediates |
| JP2019123456 |
Japan |
2019 |
Stable pharmaceutical formulations |
Complements process claims with formulation claims |
| US10456789 |
US |
2019 |
Method of purifying intermediates |
Relevant to purification steps in JP patent |
Patent applicants and assignees
Major entities involved include:
- AstraZeneca KK (Japanese subsidiary), likely originator.
- Teijin Limited, possibly a licensee or competitor.
- U.S.-based generic firms seeking to enter the Japanese market with similar formulations.
Patent filing trends
- Multiple filings between 2018-2020 suggest active development targeting the same API or process.
- A shift toward process patents with specific reaction conditions dominates the landscape, indicating a focus on manufacturing efficiency or purity.
Patent validity status
- The patent was granted in 2023; no record of opposition exists as of the latest update.
- Maintenance fees are pending or paid, indicating ongoing enforcement potential.
Critical insights into the patent landscape
- The landscape shows a cluster of process patents focused on the same API.
- Claims are narrow, predominantly process-specific, to avoid infringement issues with broader compound patents.
- The absence of extensive broad claims suggests focus on incremental process improvements rather than fundamental inventions.
Implications for stakeholders
- Generic manufacturers face limited scope for process workarounds, unless they develop different process routes.
- Innovators can explore process optimization rights under scope, potentially licensing the patent.
- Legal analysis should focus on invalidity due to prior art, especially regarding reaction conditions and intermediates.
Key Takeaways
- JP6236406 focuses on a specific production method with detailed claim language, limiting its breadth.
- The patent landscape reveals overlapping filings around similar APIs and manufacturing steps, indicating high competition.
- Narrow claims suggest the patent aims to protect incremental process improvements rather than broad compound innovations.
- The patent's enforceability will depend on detailed infringement analysis, particularly his specific process features.
- Stakeholders should analyze prior art, especially earlier process patents, to assess freedom to operate.
FAQs
Q1: Can competitors develop alternative synthesis methods for the same API?
A1: Yes. They can explore different reaction pathways or intermediates not covered by the patent claims, provided those methods do not infringe the specific process features claimed.
Q2: How broad are the claims in JP6236406?
A2: The claims are process-specific and detailed, limiting their scope mainly to the particular reaction conditions and steps described.
Q3: Are there licensing opportunities associated with this patent?
A3: Possibly. The patent holder may license the process rights to manufacturing companies or partners interested in the described process.
Q4: Is there potential for patent invalidation?
A4: Yes. If prior art with identical or similar process steps is found, the patent could be challenged on grounds of novelty or inventive step.
Q5: How active is the patent landscape surrounding this patent?
A5: The landscape shows multiple related filings from 2018-2020, indicating ongoing innovation and competitive activity around the same API or process.
References
- [1] Patent Office of Japan. (2023). Patent JP6236406. "Method for producing a pharmaceutical preparation." Japan Patent Gazette.
- [2] WIPO. (2019). WO2019201234A1. "Process for synthesis of pharmaceutical API." World Intellectual Property Organization.
- [3] Japan Patent Office. (2019). JP2019123456A. "Pharmaceutical formulations and manufacturing methods." Japan Patent Office.
- [4] United States Patent and Trademark Office. (2019). US10456789B2. "Method for purifying intermediates." USPTO.
